The overall clinical success rate of arthroscopic capsular release (ACR) for refractory adhesive capsulitis is exceptionally high, typically ranging between 80% and 95%.

Clinical studies, including long-term data published in The Journal of Bone and Joint Surgery (JBJS), demonstrate that the vast majority of patients experience significant, rapid, and sustained improvements in both pain relief and shoulder range of motion (ROM) after failing conservative therapy.

Pain relief occurs remarkably fast following arthroscopic release:

• Within 1 week: Approximately 50% of patients achieve good pain relief.
• Within 6 weeks: Up to 80% of patients report significant, complete, or near-complete pain relief.
• Sleep Restoration: Research indicates that while 0% of patients could sleep through the night pre-operatively, up to 90% achieved uninterrupted sleep within a mean of 12 days post-surgery.

The average preoperative Visual Analogue Scale (VAS) pain score typically drops from 6.6/10 to 1.0/10 within weeks of the procedure.

Yes, the clinical benefits are highly durable. Long-term follow-up studies (averaging 7 years post-operatively, with ranges up to 13 years) confirm that the early gains in range of motion, functional scores, and pain reduction are fully maintained or enhanced over time.

Unlike non-operative courses which can leave permanent minor deficits, long-term post-operative shoulder mobility in patients who underwent ACR routinely reaches equivalence with their healthy, contralateral shoulder.

While both procedures yield significant functional improvements, arthroscopic capsular release (ACR) consistently demonstrates superior early outcomes compared to MUA combined with hydrodilatation:

• Early ROM: ACR patients demonstrate significantly faster early recovery of abduction and flexion.
• Visual Control: ACR allows direct visualization of the capsule, eliminating the risk of iatrogenic injuries (such as humerus fractures or labral tearing) associated with the blunt force of MUA.
• Patient Satisfaction: Subjective satisfaction rates are statistically higher in patients undergoing arthroscopic intervention.

Diabetes mellitus is a well-known risk factor for severe adhesive capsulitis. Patients with diabetes often present with more advanced pathological changes:

• They demonstrate more severe synovitis and thicker, more fibrotic capsules.
• They commonly exhibit advanced adhesions of the coracohumeral ligament over the long head of the biceps.

The Outcome: While diabetic patients still achieve excellent functional gains and high satisfaction rates post-surgery, their average postoperative American Shoulder and Elbow Surgeons (ASES) scores may be slightly lower than non-diabetics, and they may experience a slower overall recovery trajectory.

The rate of recurrent, clinically significant stiffness requiring secondary surgical intervention is remarkably low, typically estimated between 5% and 8%.

Recurrent stiffness is usually managed successfully with an early manipulation under anesthesia (MUA) roughly 4 to 6 weeks post-surgery to break down early micro-adhesions, without requiring a complete revision arthroscopy.

Systematic reviews and comparative trials suggest that less extensive releases (such as releasing the anterior capsule, rotator interval, and coracohumeral ligament) often perform just as well as full, circumferential 360-degree releases.

While adding a posterior capsular release can provide a temporary boost in early postoperative internal rotation and flexion, meta-analyses demonstrate no significant difference in long-term range of motion, pain scores (VAS), or complication rates between a partial and a complete 360-degree release.

Arthroscopic capsular release is highly safe, with a total complication rate below 2%. Potential risks include:

• Axillary Nerve Injury: The axillary nerve lies close to the infero-anterior capsule. Experienced surgeons minimize this risk by utilizing safe ablation parameters and precise structural landmarks.
• Transient Instability: Extremely rare, occurring if the inferior or posterior structures are over-released.
• Local Infection: General surgical risk, minimized via arthroscopic fluid irrigation and sterile techniques.

Return-to-work timelines are rapid for most patients:

• Week 1: ~39% of patients return to work (primarily sedentary/desk-based roles).
• Week 2: ~58% of patients have returned.
• Week 3: ~69% of patients have returned.

Heavy manual laborers or those requiring significant overhead reaching typically require 6 to 12 weeks of recovery and targeted physical therapy before safely returning to full-duty work.

Post-operative physical therapy is **absolutely critical** to the overall success of the procedure. The surgery mechanically releases the tight tissue, but immediate movement is required to keep it from scabbing and healing back together.

Standard protocols dictate that gentle passive and active range of motion (ROM) exercises must begin on Post-Operative Day 1. Delaying physical therapy by even a few days can significantly lower the overall success rate and lead to early recurrent stiffness.